Cellenkos

Focus: Cellenkos is a Houston-based biotechnology company founded in 2024 specializing in cord blood cell therapy for gene therapy and cell therapy applications. The company is publicly listed but remains in early-stage development with no marketed products.

Gene Therapy Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$15M

Open Jobs

About Cellenkos

AI assessmentNot Hiring

No open roles listed right now. Follow Cellenkos to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CK0801

Guillain-Barré Syndrome

Phase 1

Clinical Trials (1)

NCT03773328A Clinical Trial of CK0801 (a New Drug) In Patients With Treatment-Resistant Guillain-Barré Syndrome (GBS)

Phase 1

Help build intelligence for Cellenkos

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly public biotech (founded 2024) with first-mover advantage in cord blood cell therapy
Diverse pipeline spanning 6 active programs across high-unmet-need indications including ALS, aplastic anemia, and GBS
Exposure to emerging cell therapy modality with significant clinical upside potential in early phases

Watch Out For

Extreme early-stage risk: only 1 Phase 2 program; 5 programs remain in Phase 1 with no Phase 3 data
Zero revenue, no disclosed funding amount, no active hiring (0 open positions), and minimal scientific publication track record (0 publications)

Generated by Claude from Cellenkos's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CK0803

Amyotrophic Lateral Sclerosis

Phase 1

Clinical Trials (1)

NCT05695521Regulatory T Cells for Amyotrophic Lateral Sclerosis

Phase 1

CK0804

Myelofibrosis

Phase 1

Clinical Trials (1)

NCT05423691Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Phase 1